To conclude, multikinase inhibitors, interfering also with FGFR1‐FGFR4, improved somewhat overall survival and clinical outcomes of advanced‐stage HCC, indicating urgent needs to carefully select HCC patients on the base of suitable biomarkers.3 The gene discussed is FGFR4; the disease is hepatocellular carcinoma.